Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
July 9, 2026 8:00 AM EDTStatistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24
FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2 and IL-15Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells
Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET
DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More
